UMB Bank N A MO raised its holdings in Stryker Co. (NYSE:SYK) by 2.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,907 shares of the medical technology company’s stock after buying an additional 218 shares during the quarter. UMB Bank N A MO’s holdings in Stryker were worth $1,650,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Firestone Capital Management bought a new stake in shares of Stryker during the fourth quarter valued at approximately $42,000. Procyon Private Wealth Partners LLC purchased a new position in shares of Stryker during the 4th quarter valued at $31,000. Lloyd Advisory Services LLC. purchased a new position in shares of Stryker during the 4th quarter valued at $33,000. ERTS Wealth Advisors LLC purchased a new stake in Stryker during the 4th quarter worth about $25,000. Finally, WASHINGTON TRUST Co bought a new position in Stryker in the 1st quarter worth about $28,000. 71.27% of the stock is currently owned by hedge funds and other institutional investors.

SYK has been the subject of several research analyst reports. JPMorgan Chase & Co. dropped their price objective on Stryker from $240.00 to $210.00 and set an “overweight” rating for the company in a report on Wednesday, April 15th. Stifel Nicolaus lifted their target price on Stryker from $145.00 to $205.00 and gave the stock a “buy” rating in a report on Friday, May 1st. UBS Group reduced their target price on Stryker from $230.00 to $202.00 and set a “neutral” rating for the company in a report on Friday, May 1st. Cfra reduced their target price on Stryker from $234.00 to $231.00 and set a “strong-buy” rating for the company in a report on Friday, May 1st. Finally, Goldman Sachs Group lowered Stryker from a “buy” rating to a “sell” rating and reduced their target price for the stock from $248.00 to $150.00 in a report on Wednesday, April 1st. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $214.23.

In related news, CFO Glenn S. Boehnlein sold 10,351 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $185.24, for a total value of $1,917,419.24. Following the completion of the transaction, the chief financial officer now owns 16,321 shares in the company, valued at approximately $3,023,302.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Srikant M. Datar sold 200 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $194.32, for a total value of $38,864.00. Following the completion of the transaction, the director now owns 17,686 shares of the company’s stock, valued at approximately $3,436,743.52. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,670 shares of company stock worth $5,775,251. Insiders own 6.80% of the company’s stock.

NYSE:SYK traded down $2.12 during mid-day trading on Friday, hitting $173.49. 362,389 shares of the company traded hands, compared to its average volume of 1,485,198. The stock’s fifty day moving average price is $190.67 and its 200-day moving average price is $193.09. Stryker Co. has a one year low of $124.54 and a one year high of $226.30. The company has a quick ratio of 1.77, a current ratio of 2.58 and a debt-to-equity ratio of 0.72. The firm has a market cap of $66.08 billion, a price-to-earnings ratio of 30.86, a price-to-earnings-growth ratio of 3.08 and a beta of 0.85.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $1.84 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.69 by $0.15. Stryker had a return on equity of 24.90% and a net margin of 14.47%. The business had revenue of $3.59 billion for the quarter, compared to the consensus estimate of $3.45 billion. During the same period in the previous year, the business earned $1.88 earnings per share. The business’s revenue was up 2.0% on a year-over-year basis. Equities analysts predict that Stryker Co. will post 6.22 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.575 per share. The ex-dividend date of this dividend is Monday, June 29th. This represents a $2.30 annualized dividend and a yield of 1.33%. Stryker’s payout ratio is currently 27.85%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: Monthly Dividend Stocks Can Provide Solid Income

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.